PTC Therapeutics, Inc.
METHOD FOR TREATING NONSENSE MUTATION MEDIATED DUCHENNE MUSCULAR DYSTROPHY IN PEDIATRIC PATIENTS
Last updated:
Abstract:
Provided herein is a method for ameliorating or managing nonsense mutation mediated Duchenne muscular dystrophy (nmDMD) in a pediatric patient in need thereof comprising, administering an effective amount of ataluren to the patient.
Status:
Application
Type:
Utility
Filling date:
9 Apr 2020
Issue date:
9 Jun 2022